Randomized phase III trial of consolidation therapy with bortezomib-lenalidomide-Dexamethasone (VRd) vs bortezomib-dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen

一项随机III期临床试验，比较硼替佐米-来那度胺-地塞米松（VRd）巩固治疗方案与硼替佐米-地塞米松（Vd）巩固治疗方案在完成地塞米松诱导治疗的多发性骨髓瘤患者中的疗效。